Zhao Hui, Li Ronghua, Wang Qiuju, Yan Qingfeng, Deng Jian-Hong, Han Dongyi, Bai Yidong, Young Wie-Yen, Guan Min-Xin
Division and Program in Human Genetics and Center for Hearing and Deafness Research, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229-3039, USA.
Am J Hum Genet. 2004 Jan;74(1):139-52. doi: 10.1086/381133. Epub 2003 Dec 12.
We report here the characterization of a large Chinese family with maternally transmitted aminoglycoside-induced and nonsyndromic deafness. In the absence of aminoglycosides, some matrilineal relatives in this family exhibited late-onset/progressive deafness, with a wide range of severity and age at onset. Notably, the average age at onset of deafness has changed from 55 years (generation II) to 10 years (generation IV). Clinical data reveal that the administration of aminoglycosides can induce or worsen deafness in matrilineal relatives. The age at the time of drug administration appears to be correlated with the severity of hearing loss experienced by affected individuals. Sequence analysis of mitochondrial DNA in this pedigree identified a homoplasmic C-to-T transition at position 1494 (C1494T) in the 12S rRNA gene. The C1494T mutation is expected to form a novel U1494-1555A base pair, which is in the same position as the C1494-1555G pair created by the deafness-associated A1555G mutation, at the highly conserved A site of 12S rRNA. Exposure to a high concentration of paromomycin or neomycin caused a variable but significant average increase in doubling time in lymphoblastoid cell lines derived from four symptomatic and two asymptomatic individuals in this family carrying the C1494T mutation when compared to four control cell lines. Furthermore, a significant decrease in the rate of total oxygen consumption was observed in the mutant cell lines. Thus, our data strongly support the idea that the A site of mitochondrial 12S rRNA is the primary target for aminoglycoside-induced deafness. These results also strongly suggest that the nuclear background plays a role in the aminoglycoside ototoxicity and in the development of the deafness phenotype associated with the C1494T mutation in the mitochondrial 12S rRNA gene.
我们在此报告一个患有母系遗传的氨基糖苷类药物诱发的非综合征性耳聋的大型中国家系的特征。在没有氨基糖苷类药物的情况下,该家系中的一些母系亲属表现出迟发性/进行性耳聋,严重程度和发病年龄范围广泛。值得注意的是,耳聋的平均发病年龄已从55岁(第二代)变为10岁(第四代)。临床数据显示,氨基糖苷类药物的使用可诱发或加重母系亲属的耳聋。给药时的年龄似乎与受影响个体所经历的听力损失严重程度相关。对该家系线粒体DNA的序列分析在12S rRNA基因的第1494位(C1494T)发现了一个纯合的C到T转换。C1494T突变预计会形成一个新的U1494 - 1555A碱基对,它与耳聋相关的A1555G突变产生的C1494 - 1555G碱基对处于相同位置,位于12S rRNA高度保守的A位点。与四个对照细胞系相比,暴露于高浓度的巴龙霉素或新霉素会导致该家系中携带C1494T突变的四名有症状和两名无症状个体的淋巴母细胞系的倍增时间出现可变但显著的平均增加。此外,在突变细胞系中观察到总氧消耗率显著降低。因此,我们的数据有力地支持了线粒体12S rRNA的A位点是氨基糖苷类药物诱发耳聋的主要靶点这一观点。这些结果还强烈表明,核背景在氨基糖苷类药物的耳毒性以及与线粒体12S rRNA基因中C1494T突变相关的耳聋表型的发展中起作用。